156 related articles for article (PubMed ID: 7584913)
1. Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension.
Ito K; Shiomi M; Kito G
Hypertens Res; 1995 Mar; 18(1):69-75. PubMed ID: 7584913
[TBL] [Abstract][Full Text] [Related]
2. Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.
Kanagawa R; Wada T; Sanada T; Ojima M; Inada Y
Jpn J Pharmacol; 1997 Mar; 73(3):185-90. PubMed ID: 9127812
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
Wada T; Inada Y; Ojima M; Sanada T; Shibouta Y; Nishikawa K
Hypertens Res; 1996 Jun; 19(2):75-81. PubMed ID: 10968199
[TBL] [Abstract][Full Text] [Related]
4. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
[TBL] [Abstract][Full Text] [Related]
5. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate. Part II: Effect on cardiovascular system and renal functions.
Kito G; Ito K; Shiomi M
Arzneimittelforschung; 1996 Jul; 46(7):681-6. PubMed ID: 8842337
[TBL] [Abstract][Full Text] [Related]
6. Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats.
Okada H; Suzuki H; Kanno Y; Ikenaga H; Saruta T
J Cardiovasc Pharmacol; 1995 Oct; 26(4):564-9. PubMed ID: 8569216
[TBL] [Abstract][Full Text] [Related]
7. Comparable effects of angiotensin II and converting enzyme blockade on hemodynamics and cardiac hypertrophy in spontaneously hypertensive rats.
Mori T; Nishimura H; Ueyama M; Kubota J; Kawamura K
Jpn Circ J; 1995 Sep; 59(9):624-30. PubMed ID: 7500546
[TBL] [Abstract][Full Text] [Related]
8. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension.
Kawabata M; Takabatake T; Ohta H; Nakamura S; Hara H; Ohta K; Takakuwa H; Han WH; Kobayashi K
Blood Press Suppl; 1994; 5():117-21. PubMed ID: 7889193
[TBL] [Abstract][Full Text] [Related]
9. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man.
Schmitt F; Natov S; Martinez F; Lacour B; Hannedouche TP
Clin Sci (Lond); 1996 Mar; 90(3):205-13. PubMed ID: 8777826
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.
Inada Y; Wada T; Ojima M; Sanada T; Shibouta Y; Kanagawa R; Ishimura Y; Fujisawa Y; Nishikawa K
Clin Exp Hypertens; 1997 Oct; 19(7):1079-99. PubMed ID: 9310205
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of hypertension and renal injury by salt-loading during chronic nitric oxide inhibition. Effects of TCV-116, a novel angiotensin II receptor antagonist.
Okamura M; Konishi Y; Nishimura M; Umetani N; Iwai J; Negoro N; Inoue T; Takeda T; Kanayama Y
Blood Press Suppl; 1994; 5():75-8. PubMed ID: 7889207
[TBL] [Abstract][Full Text] [Related]
12. Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects.
Ogihara T; Nagano M; Mikami H; Higaki J; Kohara K; Azuma J; Aoki T; Hamanaka Y
Clin Ther; 1994; 16(1):74-86. PubMed ID: 8205603
[TBL] [Abstract][Full Text] [Related]
13. Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats.
Mizuno K; Niimura S; Tani M; Saito I; Sanada H; Takahashi M; Okazaki K; Yamaguchi M; Fukuchi S
Life Sci; 1992; 51(20):PL183-7. PubMed ID: 1435062
[TBL] [Abstract][Full Text] [Related]
14. Chronic effects of ANG II antagonist in heart failure: improvement of cGMP generation from ANP.
Maeda Y; Wada A; Tsutamoto T; Fukai D; Kinoshita M
Am J Physiol; 1997 May; 272(5 Pt 2):H2139-45. PubMed ID: 9176279
[TBL] [Abstract][Full Text] [Related]
15. Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects.
Ogihara T; Nagano M; Higaki J; Kohara K; Mikami H
J Cardiovasc Pharmacol; 1995 Sep; 26(3):490-4. PubMed ID: 8583793
[TBL] [Abstract][Full Text] [Related]
16. Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury.
Kim S; Ohta K; Hamaguchi A; Omura T; Yukimura T; Miura K; Inada Y; Wada T; Ishimura Y; Chatani F
Kidney Int; 1994 Nov; 46(5):1346-58. PubMed ID: 7853793
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs.
Hayashi N; Yamamoto S; Kometani M; Nakao K
Arzneimittelforschung; 1997 May; 47(5):620-5. PubMed ID: 9205775
[TBL] [Abstract][Full Text] [Related]
18. TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats.
Mizuno K; Niimura S; Katoh K; Fukuchi S
Life Sci; 1994; 54(25):1987-94. PubMed ID: 8201847
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the high sensitivity of rabbits to the effects of TCV-116, an angiotensin II receptor antagonist.
Sato K; Chatani F; Ito K; Kito G
Fundam Appl Toxicol; 1997 Jan; 35(1):49-54. PubMed ID: 9024672
[TBL] [Abstract][Full Text] [Related]
20. TCV 116 prevents progressive renal injury in rats with extensive renal mass ablation.
Mackenzie HS; Troy JL; Rennke HG; Brenner BM
J Hypertens Suppl; 1994 Nov; 12(9):S11-6. PubMed ID: 7884578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
